Empathx Clinical Research has become part of hyperCORE International's global partner site network, expanding the clinical research organization's patient reach and capabilities across multiple U.S. states. The Tampa Bay-based organization operates eight clinical trial sites across California, Florida, Massachusetts, Michigan, Missouri, and Texas, focusing on advancing trials in cardio-metabolic disease, central nervous system disorders, nephrology, and infectious disease.
The organization employs a hybrid model that includes both dedicated research centers and integrated research sites embedded within large, specialized physician practices. This approach brings clinical research directly into care environments where patients already receive treatment, potentially expanding access to trials while supporting efficient study execution. According to hyperCORE International President Nicholas Focil, this integration aligns with the network's mission to expand patient access and deliver high-quality trials.
Empathx CEO Dustin Owen emphasized that joining hyperCORE reflects a shared commitment to collaboration and quality among leading research site networks. "The partnership enhances our ability to work with sponsors to bring life-changing therapies to our communities," Owen stated. "Our added scale, geographic coverage, and access to diverse patient populations gives sponsors a reliable solution for delivering on clinical trials." Owen previously served as Senior Vice President of Accelerated Enrollment Solutions at Thermo Fisher Scientific/PPD, where he led global clinical research site operations.
hyperCORE International represents a network of leading clinical research organizations with more than 80 active trial sites across five countries. According to information available at https://hypercoreintl.com, the network's partners have collectively completed over 7,000 studies involving more than 140,000 randomized participants. The network aligns independent organizations around harmonized operational frameworks designed to support high-quality, consistent trial execution.
The addition of Empathx Clinical Research to hyperCORE's network brings increased therapeutic expertise and geographic reach to the partnership. This expansion could potentially accelerate clinical trial timelines by providing sponsors with access to diverse patient populations across multiple states. The integration of research sites within existing clinical care environments may also improve patient recruitment and retention, addressing common challenges in clinical research execution.
For the clinical research industry, this partnership represents continued consolidation and collaboration among research organizations seeking to improve trial efficiency and patient access. The combined capabilities of hyperCORE's international network and Empathx's U.S. presence could offer pharmaceutical companies and research sponsors more comprehensive solutions for conducting multi-site trials. This development comes as the clinical research sector increasingly focuses on decentralized trial models and improved patient accessibility.
hyperCORE International maintains a commitment to advancing clinical research through safe, ethical studies, strong enrollment, and superior patient retention. The network's expansion through partnerships like this one with Empathx Clinical Research reflects ongoing efforts to streamline clinical trial processes and bring new therapies to market more efficiently. Additional details about hyperCORE's network and partnerships can be found through their official communications channels.
